Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN/NN2 and Tdap Coadministration in Healthy Non-Pregnant Women
NCT06494475Phase 3Withdrawn
- Sponsor
- MinervaX
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of GBS-NN/NN2 vaccine in Streptococcus agalactiae infection (GBS), sponsored by MinervaX. Planned start Dec 2024; status: withdrawn.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on NCT06494475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494475.